.png?h=522&iar=0&w=556&rev=-1&hash=031A38E538D6391EFF5CF12B28042613)
Crowe HAF assisted Odyssée Venture in its acquisition
of a stake in Datexim as part of a €1.5 million
fundraising campaign.
Founded in 2011 and specialized in the treatment and
analysis of medical imaging, Datexim has developed a
cervical cancer screening solution based on artificial
intelligence.
After eight years of R&D, Datexim wishes to conquer
the market in France and Europe.